A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 18 Jun 2017 Status changed from not yet recruiting to recruiting.
- 05 Apr 2017 Planned initiation date changed from 1 Mar 2017 to 1 Apr 2017.